Seaport Therapeutics announced the publication of clinical and preclinical data for its drug candidate GlyphAllo in Science Translational Medicine. The company reported that GlyphAllo represents the first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans.

GlyphAllo is an oral prodrug of allopregnanolone designed to treat major depressive disorder. The drug uses Seaport's Glyph platform technology, which enables oral administration by utilizing the lymphatic system to bypass liver metabolism.

The published research details Phase 1 clinical trial results showing GlyphAllo was generally well-tolerated at oral doses ranging from 70-1000 mg and provided therapeutically relevant plasma exposures of allopregnanolone. In a Phase 2a proof-of-concept trial using the Trier Social Stress Test, a single 375 mg dose of GlyphAllo significantly reduced salivary cortisol levels compared to placebo.

"GlyphAllo is our lead investigational product candidate designed to overcome the bioavailability limitations of allopregnanolone and deliver rapid and durable clinical effects," said Steven Paul, co-founder and board chair at Seaport Therapeutics.

The company initiated BUOY-1, a Phase 2b trial evaluating GlyphAllo in adults with major depressive disorder in July 2025. The randomized, double-blind, placebo-controlled study will assess efficacy, safety and tolerability of the drug candidate.

Seaport Therapeutics is a founded entity of PureTech Health (NASDAQ: PRTC, LSE: PRTC). The Glyph platform was initially developed at PureTech before being advanced by Seaport. The technology was originally licensed from Monash University.